electroCore Inc. (ECOR)
NASDAQ: ECORHealth CareBiotechnology: Electromedical & Electrotherapeutic ApparatusUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ECOR stock chart
Technical analysisKey statistics
All statistics- Market cap
- $40.78M
- EPS (TTM)
- -$1.36
- Dividend yield
- None
- 52-week range
- 3.90 – 12.70
- Day range
- 3.90 – 4.97
- Volume / Avg
- 631.55K / 120.32K
- Beta
- —
- Shares outstanding
- 9.23M
52-week range
ECOR stock today
On Nov 20, ECOR ended the session at $4.42, shedding $0.43 (8.87%), versus the S&P 500's 3.70% decline. Volume was 5.2x the average at 631.55K shares, a sign of unusually heavy trading. Shares are 65.2% below their 52-week high of $12.70, set on Sep 22, 2026 and 13.3% above the 52-week low of $3.90, near the bottom of the past year's range.
ECOR is down 1.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 6.2%. electroCore has posted a net loss over the last twelve months (EPS of -$1.36), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About electroCore
Company profileelectroCore, Inc., a bioelectronic technology medicine and general wellness company, provides non-invasive vagus nerve stimulation (nVNS) technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga 350, a personal use consumer electronics general wellness product and Truvaga Plus, an app-enabled general wellness product.
- Sector
- Health Care
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- CEO
- Mr. Joshua S. Lev
- Headquarters
- Rockaway, NJ
- Employees
- 83
- IPO year
- 2018
- Website
- electrocore.com
Financial highlights
Full financialsIn fiscal 2025, electroCore generated $32.0 million in revenue, up 27.2% from fiscal 2024, its 8th consecutive year of revenue growth. electroCore reported a net loss of $14.0 million, compared with a loss of $11.9 million a year earlier. Gross margin was 86.8% (up from 85.0%) and operating margin -41.1%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $32.03M | $25.18M | $16.03M | $8.59M | $5.45M |
| Growth | +27.20% | +57.09% | +86.57% | +57.62% | +55.93% |
| Net income | $-13.97M | $-11.89M | $-18.83M | $-22.16M | $-17.22M |
| EPS (diluted) | $-1.65 | $-1.59 | $-3.42 | $-4.69 | $-4.36 |
Analyst forecast
ForecastConsensus (5 analysts)
none
Avg. price target
$19.17+333.71%
- Strong buy 1
- Buy 4
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $-0.13 vs $-0.26
- Surprise
- +50.00%
ECOR news
All ECOR news- Randomized Study of Non-Invasive Autonomic Neuromodulation for Long COVID Published Online in NeuromodulationGlobeNewswire
- electroCore (ECOR) Q3 2026 Earnings Call TranscriptNasdaq
- electroCore Announces Third Quarter 2026 Financial ResultsGlobeNewswire
- Neurocrine Biosciences (NBIX) Q3 Earnings and Revenues Top EstimatesNasdaqNBIX, ECOR
- ElectroCore Files FDA Submission For Quell In Persistent Chemotherapy-Related Neuropathy; Stock UpNasdaqECOR, BRK.B
electroCore peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| POCIPrecision Optics Corporation Inc. | 4.12 | +1.41% | $45.30M | vs ECOR |
| OMOutset Medical Inc. | 2.81 | -3.44% | $53.03M | vs ECOR |
| QTIQT Imaging Holdings Inc. | 1.92 | +2.67% | $28.21M | vs ECOR |
| HYPRHyperfine Inc. Class A | 0.5465 | +4.27% | $57.96M | vs ECOR |
| NRXSNeuraxis Inc. | 4.22 | -6.22% | $59.90M | vs ECOR |
| ITOCiTonic Holdings Ltd Class A | 1.59 | +6.00% | $11.63M | vs ECOR |
| IRIXIRIDEX Corporation | 0.4449 | -4.59% | $7.92M | vs ECOR |
| NDRAENDRA Life Sciences Inc. | 3.58 | -3.38% | $5.36M | vs ECOR |
Indexes, lists and sector
electroCore stock FAQ
What is electroCore's stock price today?
ECOR last traded at $4.42 as of Nov 20, 4:00 PM EST, down 8.87% on the day. Prices are delayed at least 15 minutes.
Does electroCore pay a dividend?
No. electroCore does not currently pay a regular cash dividend.
Who is electroCore's CEO?
Mr. Joshua S. Lev is the chief executive officer of electroCore Inc., which has about 83 employees.
Has ECOR ever split its stock?
Yes. The most recent ECOR stock split was a 1-for-15 split on Feb 15, 2023.
What is the ECOR 52-week high?
The 52-week high for ECOR is $12.70 and the 52-week low is $3.90. The stock is currently 65.2% below its high.